Recent News

• 04.22.2025 - Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee
• 04.22.2025 - Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee
• 04.22.2025 - Oren Livnat
• 04.17.2025 - Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
• 04.17.2025 - Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
• 04.11.2025 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.11.2025 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.07.2025 - Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
• 04.07.2025 - Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
• 04.07.2025 - 24th Annual Needham Virtual Healthcare Conference

Recent Filings

• 04.22.2025 - 8-K Current report
• 04.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.18.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.07.2025 - EX-99.1 EX-99.1
• 04.07.2025 - 8-K Current report